Deviere J
Department of Gastroenterology and Hepatopancreatology, ULB - Hôpital Erasme, Route de Lennik 808, B - 1070 Brussels, Belgium.
Gut. 2005 Mar;54 Suppl 1(Suppl 1):i33-7. doi: 10.1136/gut.2004.041574.
Barrett's oesophagus is defined as the replacement of squamous oesophageal epithelium by intestinal metaplasia in the distal oesophagus. It is a fairly frequent complication of gastro-oesophageal reflux disease (GORD): 5-10% of patients with GORD suffer from Barrett's oesophagus. GORD is essential for the development of Barrett's oesophagus.1 Intestinal metaplasia is a premalignant lesion that may further develop into dysplasia and lead to adenocarcinoma of the oesophagus. The latter now accounts for almost 50% of oesophageal cancer cases in western countries, and the largest increase in its incidence was recorded during the past two decades. Patients with Barrett's oesophagus have a 2-25% risk of developing mild to severe dysplasia and a 2-5% risk of having adenocarcinoma: 30-150 times higher than the risk in the general population. Forty to fifty per cent of Barrett's oesophagus patients with severe dysplasia would present adenocarcinoma within 5 years.
巴雷特食管的定义为远端食管的鳞状上皮被肠化生所取代。它是胃食管反流病（GORD）相当常见的并发症：5%至10%的GORD患者患有巴雷特食管。GORD是巴雷特食管发生的必要条件。肠化生是一种癌前病变，可能进一步发展为发育异常并导致食管腺癌。在西方国家，后者目前占食管癌病例的近50%，其发病率在过去二十年中增长最为显著。巴雷特食管患者发生轻度至重度发育异常的风险为2%至25%，患腺癌的风险为2%至5%：比普通人群的风险高30至150倍。40%至50%的重度发育异常的巴雷特食管患者将在5年内出现腺癌。
